ArticleHemaSphere2025

Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.

Corentin Orvain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.